AYTU BIOPHARMA, INC AYTU

About AYTU BIOPHARMA, INC (AYTU): stock profile, AI score and financials

AYTU BIOPHARMA, INC (AYTU) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AYTU at 28.8/100 on a composite quality score built from its SEC filings, placing it at rank #2,512 of 2,925 stocks — the bottom half of the AI-ranked universe. AYTU scores in the top quartile across institutional flow (99.5). Areas of concern include revenue scale (10.3) and revenue growth (12.3), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q4 2026), AYTU BIOPHARMA, INC reports quarterly revenue of $16.1M, net income of $-15.0K, an operating margin of -4.8%. Top institutional holders of AYTU by reported 13-F value include Stonepine Capital Management, Nantahala Capital Management, AWM Investment Company, based on the most recent SEC filings. AYTU trades on the Nasdaq exchange and files with the SEC under CIK 1385818. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AYTU daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AYTU BIOPHARMA, INC directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1385818 →